Is Repligen Corporation (RGEN) overvalued? · P/E 143, $7.43B cap
Repligen Corporation (RGEN) is a medical instruments & supplies company listed on NASDAQ.
This page asks whether Repligen Corporation (RGEN) looks expensive on cached numbers — not a short thesis.
No cached income statement for RGEN, so there is no earnings base to call rich or cheap.
RGEN currently screens at market cap $7.43B and trailing P/E 143.1. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RGEN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RGEN stock page for the full model, not this heading.
Not investment advice.